Effectiveness, safety, and cost of vancomycin and linezolid in Kuwait: A retrospective cohort study
Background: The effectiveness, safety, and cost of vancomycin and linezolid for managing gram-positive bacterial infections in Kuwait are unknown. This study assessed the effectiveness, safety, and cost of vancomycin, teicoplanin and linezolid for managing gram-positive bacterial infections in Kuwai...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-11-01
|
| Series: | Saudi Pharmaceutical Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1319016423003080 |
| _version_ | 1797632709129928704 |
|---|---|
| author | Sarah S. Alghanem Moetaza M. Soliman Sarah Al-Manie Wadha Alfouzan Duaa Alhammadi Yousif Alreshidi Adnan Hajjiah Rafaa Alfarhoud Mai Almane Mona Mataqi Salma Alajmi Khalifa Albenwan |
| author_facet | Sarah S. Alghanem Moetaza M. Soliman Sarah Al-Manie Wadha Alfouzan Duaa Alhammadi Yousif Alreshidi Adnan Hajjiah Rafaa Alfarhoud Mai Almane Mona Mataqi Salma Alajmi Khalifa Albenwan |
| author_sort | Sarah S. Alghanem |
| collection | DOAJ |
| description | Background: The effectiveness, safety, and cost of vancomycin and linezolid for managing gram-positive bacterial infections in Kuwait are unknown. This study assessed the effectiveness, safety, and cost of vancomycin, teicoplanin and linezolid for managing gram-positive bacterial infections in Kuwait. Research design and methods: This retrospective study included adult patients who were prescribed antibiotics (vancomycin, teicoplanin, and linezolid) for the treatment of gram-positive infections at five hospitals in Kuwait. Descriptive statistics were used to assess the effectiveness and safety outcomes. A cost analysis was performed on the patients hospitalised for gram-positive infections. Results: Among 116 patients, 42.2 % (n = 49) received glycopeptides (vancomycin [n = 45] and teicoplanin [n = 4]) or linezolid (n = 67). Clinical cure was achieved in 100 patients without significant intergroup differences (p = 0.34). Thrombocytopenia and acute kidney injury occurred in 19 and 20 patients (p = 0.82 and 0.96), respectively, and their incidence was similar with all the studied agents. The average cost per patient was USD 983.70. The estimated total direct medical costs were USD 894,570.6, the cost was highest for linezolid (USD 469,682.30) and vancomycin (USD 370,342.5), and lowest for teicoplanin (USD 20,799.9). Conclusions: Glycopeptides and linezolid were highly effective. Linezolid was the most frequently prescribed agent; its effectiveness and safety were similar according to the antibiotic class. However, treatment with linezolid and vancomycin were associated with considerable costs. |
| first_indexed | 2024-03-11T11:41:39Z |
| format | Article |
| id | doaj.art-8f6ddd3c9321476ab91cc5fa379baddf |
| institution | Directory Open Access Journal |
| issn | 1319-0164 |
| language | English |
| last_indexed | 2024-03-11T11:41:39Z |
| publishDate | 2023-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Saudi Pharmaceutical Journal |
| spelling | doaj.art-8f6ddd3c9321476ab91cc5fa379baddf2023-11-10T04:16:04ZengElsevierSaudi Pharmaceutical Journal1319-01642023-11-013111101813Effectiveness, safety, and cost of vancomycin and linezolid in Kuwait: A retrospective cohort studySarah S. Alghanem0Moetaza M. Soliman1Sarah Al-Manie2Wadha Alfouzan3Duaa Alhammadi4Yousif Alreshidi5Adnan Hajjiah6Rafaa Alfarhoud7Mai Almane8Mona Mataqi9Salma Alajmi10Khalifa Albenwan11Department of Pharmacy Practice, College of Pharmacy, Kuwait University, Safat 13110 Kuwait; Corresponding author at: Department of Pharmacy Practice, College of Pharmacy at Kuwait University, PO Box 24923, Safat 13110, Kuwait.Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Mansoura University, EgyptDepartment of Pharmacy Practice, College of Pharmacy, Kuwait University, Safat 13110 KuwaitDepartment of Microbiology, College of Medicine, Kuwait University, Safat 13110 Kuwait; Department of Microbiology, Al-Farwania Hospital, Kuwait Ministry of Health, KuwaitDepartment of Pharmacy, Mubarak Alkabeer Hospital, Kuwait Ministry of Health, KuwaitDepartment of Pharmacy, Mubarak Alkabeer Hospital, Kuwait Ministry of Health, KuwaitDepartment of Pharmacy, Ahmadi Hospital, Kuwait Oil Company, KuwaitDepartment of Pharmacy, Ahmadi Hospital, Kuwait Oil Company, KuwaitDepartment of Pharmacy, Zain Hospital, Kuwait Ministry of Health, KuwaitDepartment of Pharmacy, Al-Adan Hospital, Kuwait Ministry of Health, KuwaitDepartment of Microbiology, Al-Adan Hospital, Kuwait Ministry of Health, KuwaitDepartment of Microbiology, College of Medicine, Kuwait University, Safat 13110 Kuwait; Department of Microbiology, Al-Amiri Hospital, Kuwait Ministry of Health, KuwaitBackground: The effectiveness, safety, and cost of vancomycin and linezolid for managing gram-positive bacterial infections in Kuwait are unknown. This study assessed the effectiveness, safety, and cost of vancomycin, teicoplanin and linezolid for managing gram-positive bacterial infections in Kuwait. Research design and methods: This retrospective study included adult patients who were prescribed antibiotics (vancomycin, teicoplanin, and linezolid) for the treatment of gram-positive infections at five hospitals in Kuwait. Descriptive statistics were used to assess the effectiveness and safety outcomes. A cost analysis was performed on the patients hospitalised for gram-positive infections. Results: Among 116 patients, 42.2 % (n = 49) received glycopeptides (vancomycin [n = 45] and teicoplanin [n = 4]) or linezolid (n = 67). Clinical cure was achieved in 100 patients without significant intergroup differences (p = 0.34). Thrombocytopenia and acute kidney injury occurred in 19 and 20 patients (p = 0.82 and 0.96), respectively, and their incidence was similar with all the studied agents. The average cost per patient was USD 983.70. The estimated total direct medical costs were USD 894,570.6, the cost was highest for linezolid (USD 469,682.30) and vancomycin (USD 370,342.5), and lowest for teicoplanin (USD 20,799.9). Conclusions: Glycopeptides and linezolid were highly effective. Linezolid was the most frequently prescribed agent; its effectiveness and safety were similar according to the antibiotic class. However, treatment with linezolid and vancomycin were associated with considerable costs.http://www.sciencedirect.com/science/article/pii/S1319016423003080CostLinezolidMethicillin-resistant Staphylococcus aureusTeicoplaninThrombocytopaeniaVancomycin |
| spellingShingle | Sarah S. Alghanem Moetaza M. Soliman Sarah Al-Manie Wadha Alfouzan Duaa Alhammadi Yousif Alreshidi Adnan Hajjiah Rafaa Alfarhoud Mai Almane Mona Mataqi Salma Alajmi Khalifa Albenwan Effectiveness, safety, and cost of vancomycin and linezolid in Kuwait: A retrospective cohort study Saudi Pharmaceutical Journal Cost Linezolid Methicillin-resistant Staphylococcus aureus Teicoplanin Thrombocytopaenia Vancomycin |
| title | Effectiveness, safety, and cost of vancomycin and linezolid in Kuwait: A retrospective cohort study |
| title_full | Effectiveness, safety, and cost of vancomycin and linezolid in Kuwait: A retrospective cohort study |
| title_fullStr | Effectiveness, safety, and cost of vancomycin and linezolid in Kuwait: A retrospective cohort study |
| title_full_unstemmed | Effectiveness, safety, and cost of vancomycin and linezolid in Kuwait: A retrospective cohort study |
| title_short | Effectiveness, safety, and cost of vancomycin and linezolid in Kuwait: A retrospective cohort study |
| title_sort | effectiveness safety and cost of vancomycin and linezolid in kuwait a retrospective cohort study |
| topic | Cost Linezolid Methicillin-resistant Staphylococcus aureus Teicoplanin Thrombocytopaenia Vancomycin |
| url | http://www.sciencedirect.com/science/article/pii/S1319016423003080 |
| work_keys_str_mv | AT sarahsalghanem effectivenesssafetyandcostofvancomycinandlinezolidinkuwaitaretrospectivecohortstudy AT moetazamsoliman effectivenesssafetyandcostofvancomycinandlinezolidinkuwaitaretrospectivecohortstudy AT sarahalmanie effectivenesssafetyandcostofvancomycinandlinezolidinkuwaitaretrospectivecohortstudy AT wadhaalfouzan effectivenesssafetyandcostofvancomycinandlinezolidinkuwaitaretrospectivecohortstudy AT duaaalhammadi effectivenesssafetyandcostofvancomycinandlinezolidinkuwaitaretrospectivecohortstudy AT yousifalreshidi effectivenesssafetyandcostofvancomycinandlinezolidinkuwaitaretrospectivecohortstudy AT adnanhajjiah effectivenesssafetyandcostofvancomycinandlinezolidinkuwaitaretrospectivecohortstudy AT rafaaalfarhoud effectivenesssafetyandcostofvancomycinandlinezolidinkuwaitaretrospectivecohortstudy AT maialmane effectivenesssafetyandcostofvancomycinandlinezolidinkuwaitaretrospectivecohortstudy AT monamataqi effectivenesssafetyandcostofvancomycinandlinezolidinkuwaitaretrospectivecohortstudy AT salmaalajmi effectivenesssafetyandcostofvancomycinandlinezolidinkuwaitaretrospectivecohortstudy AT khalifaalbenwan effectivenesssafetyandcostofvancomycinandlinezolidinkuwaitaretrospectivecohortstudy |